A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
Chari A et al. Cancer. 2016 Jul 19. doi: 10.1002/cncr.30174. [Epub ahead of print].
T cells expressing an anti-B-cell-maturation-antigen chimeric antigen receptor cause remissions of multiple myeloma.
Ali SA et al. Blood. 2016 Jul 13. pii: blood-2016-04-711903. [Epub ahead of print].